Flawed evidence underpins approval of new cancer drugs

被引：11
作者：
Mintzes, Barbara [1 ,2 ]
Vitry, Agnes [3 ]
机构：
[1] Univ Sydney, Fac Med & Hlth, Sch Pharm, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Med & Hlth, Charles Perkins Ctr, Sydney, NSW 2006, Australia
[3] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2019年 / 366卷
关键词：
SURROGATE END-POINTS; AMERICAN SOCIETY; ONCOLOGY; ASSOCIATION; SURVIVAL; STRENGTH;
D O I：
10.1136/bmj.l5399
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pioglitazone and bladder cancer in human studies: Is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
    Tseng, Chin-Hsiao
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2012, 111 (03) : 123 - 131
  • [22] Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study
    Xie, Jinping
    Li, Jinlian
    Liu, Yue
    Wang, Haoyang
    Wang, Yifei
    Yang, Yifan
    Chen, Yi
    Jiang, Rong
    Shao, Rong
    [J]. BMJ OPEN, 2023, 13 (06):
  • [23] Approval probabilities and regulatory review patterns for anticancer drugs in the European Union
    Hartmann, Markus
    Mayer-Nicolai, Christine
    Pfaff, Otmar
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) : 112 - 121
  • [24] Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
    Zhang, Yichen
    Naci, Huseyin
    Wagner, Anita K.
    Xu, Ziyue
    Yang, Yu
    Zhu, Jun
    Ji, Jiafu
    Shi, Luwen
    Guan, Xiaodong
    [J]. JAMA NETWORK OPEN, 2022, 5 (08) : E2225973
  • [25] Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015
    Vivot, A.
    Jacot, J.
    Zeitoun, J. -D.
    Ravaud, P.
    Crequit, P.
    Porcher, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (05) : 1111 - 1116
  • [26] Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs
    Bentley, Tanya G. K.
    Cohen, Joshua T.
    Elkin, Elena B.
    Huynh, Julie
    Mukherjea, Arnab
    Neville, Thanh H.
    Mei, Matthew
    Copher, Ronda
    Knoth, Russell
    Popescu, Ioana
    Lee, Jackie
    Zambrano, Jenelle M.
    Broder, Michael S.
    [J]. VALUE IN HEALTH, 2017, 20 (02) : 200 - 205
  • [27] Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
    Ling, Kexin
    Qin, Huli
    Feng, Yiman
    Che, Hongxi
    Ding, Jinxi
    Li, Wei
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [28] Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States
    Salcher-Konrad, Maximilian
    Naci, Huseyin
    Davis, Courtney
    [J]. MILBANK QUARTERLY, 2020, 98 (04) : 1219 - 1256
  • [29] Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
    Cherla, Avi
    Naci, Huseyin
    Kesselheim, Aaron S.
    Gyawali, Bishal
    Mossialos, Elias
    [J]. JAMA INTERNAL MEDICINE, 2021, 181 (04) : 490 - 498
  • [30] Apropos of the exceptionality of new cancer drugs
    Cabiedes Miragaya, Laura
    [J]. GACETA SANITARIA, 2013, 27 (01) : 84 - 88
12345